Context Therapeutics (CNTX)
0.30
0.00 (0.00%)
Upcoming Events
Latest Headlines
Context Therapeutics doses first patient in CT-202 Phase 1 trial
September 9, 2026 7:30 AM - StreetInsider
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
September 9, 2026 7:30 AM - StreetInsider
Form SCHEDULE 13G/A Context Therapeutics Filed by: MPM BioImpact LLC
August 14, 2026 4:07 PM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Blue Owl Capital Holdings LP
August 12, 2026 4:31 PM - SEC Filing
Context Therapeutics Inc. (CNTX) Misses Q2 EPS by 6c
August 6, 2026 2:45 AM - StreetInsider
Form 8-K Context Therapeutics For: Aug 05
August 5, 2026 4:21 PM - SEC Filing
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
August 5, 2026 4:14 PM - Globe NewsWire
Form 10-Q Context Therapeutics For: Jun 30
August 5, 2026 4:14 PM - SEC Filing
Context Therapeutics gets Nasdaq minimum bid price deficiency notice
July 31, 2026 4:11 PM - StreetInsider
Form 8-K Context Therapeutics For: Jul 29
July 31, 2026 4:09 PM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Octagon Capital Advisors LP
July 31, 2026 4:01 PM - SEC Filing
Form SCHEDULE 13G Context Therapeutics Filed by: BlackRock, Inc.
July 27, 2026 4:27 PM - SEC Filing
Full Article List
